Previous 10 | Next 10 |
2024-05-09 04:37:00 ET After steadily raising its payout by 163% over the past 15 years, Pfizer (NYSE: PFE) continues to be one of the most reliable pharma stocks an income-seeking investor can reach for these days. The company is a pharmaceutical giant with many parts moving in dif...
2024-05-08 10:46:32 ET More on Pfizer Pfizer: A 6% Yield And At 10-Year Lows Pfizer Stock: Not A Value Trap, Here's Why Pfizer: Solid Earnings, But We're Not Out Of The Woods Yet Boy given Pfizer experimental Duchenne muscular dystrophy therapy dies P...
2024-05-08 10:37:16 ET Summary Pfizer's stock has experienced significant fluctuations in the past 4 years, with opportunities for investors to buy low and sell high. The market has driven Pfizer's price to a 10-year low. Pfizer's focus on oncology and its strong pipeline of n...
2024-05-08 08:30:00 ET Summary Pfizer Inc.'s COVID vaccine revenue plunged to $354M in Q1, indicating a dramatic reset. It should help Pfizer potentially outperform moving ahead as it laps easier comps. Pfizer is a fundamentally strong stock with a dividend yield of almost 6%....
PALM BEACH, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - There is much activity in finding better ways in mitigating muscle loss for the cancer patients… many clinical studies are looking for elite performance nutritional supplements to mitigate the m...
2024-05-08 07:16:00 ET Healthcare doesn't get the hype that other industries -- say, technology -- get. However, there arguably isn't an industry more important to humankind's well-being. That's especially true in the United States, the world's most lucrative healthcare market -- a multi-tr...
2024-05-08 07:06:13 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca invests $140M in Cellectis, raising stake to 44% ...
2024-05-07 21:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-07 20:26:14 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-05-07 16:16:50 ET More on Pfizer, Sarepta Pfizer: Solid Earnings, But We're Not Out Of The Woods Yet Pfizer: Ignore The Dead Cat Bounce Pfizer Stock: Finally The Market Is Waking Up Pfizer hires Citi healthcare analyst Baum to lead strategy and innovatio...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...